Insomnia in Pregnancy: Recommended Treatments

First-Line Treatment: Cognitive Behavioral Therapy for Insomnia (CBT-I)

The American Academy of Sleep Medicine recommends Cognitive Behavioral Therapy for Insomnia (CBT-I) as the first-line treatment for insomnia during pregnancy, which should be initiated before any pharmacological intervention, due to its favorable risk-benefit ratio 1, 2, 3, 4.
CBT-I demonstrates significant efficacy in reducing insomnia symptoms, improving sleep efficiency, and addressing comorbidities like depression and anxiety in pregnant women, with benefits sustained up to 2 years beyond treatment end 1, 2, 5.

Sleep restriction therapy, a core component of CBT-I, limits time in bed to match actual sleep time, consolidating sleep and increasing sleep drive, and is recommended by the American Academy of Sleep Medicine 5, 4.
Stimulus control therapy, another key component, re-establishes the bed as a cue for sleep rather than wakefulness, and is supported by evidence from the Journal of Clinical Sleep Medicine 5, 4.

The American College of Obstetricians and Gynecologists suggests that pharmacological treatment should only be considered when CBT-I is insufficient, unavailable, or while CBT-I is being implemented, and should supplement—not replace—behavioral interventions, due to limited pregnancy-specific safety data 1, 6.
Ramelteon (8 mg) may be considered for sleep onset insomnia in pregnant women, despite limited pregnancy-specific data, as it has a different mechanism of action (melatonin receptor agonist) 6.

Long-acting benzodiazepines carry increased risks without clear benefit, including prolonged neonatal sedation, and are not recommended by the American Academy of Sleep Medicine 1.
Antipsychotics should not be used as first-line treatment due to problematic metabolic side effects and lack of indication for primary insomnia, as stated by the American Psychiatric Association 1.

The American Academy of Sleep Medicine recommends initiating CBT-I immediately through the most accessible format, and implementing comprehensive sleep hygiene, including regular sleep-wake schedule and optimized sleep environment 1, 2.
Medication should be used at the lowest effective dose for the shortest duration possible, typically less than 4 weeks for acute exacerbations, and should supplement behavioral treatment, as recommended by the American College of Obstetricians and Gynecologists 1, 6.

The American Academy of Sleep Medicine advises against starting with medications before attempting CBT-I, as this violates guideline recommendations and deprives pregnant women of more effective, durable therapy with no fetal risk 1, 2.
The American College of Obstetricians and Gynecologists recommends against relying on sleep hygiene education alone, as it lacks efficacy as a single intervention and must be combined with other CBT-I components 1, 2.

CBT-I can be delivered through multiple accessible formats, including individual therapy, group sessions, telephone-based programs, web-based modules, or self-help books, demonstrating effectiveness for pregnant women with insomnia 7
Over-the-counter antihistamines, such as diphenhydramine, are not recommended due to lack of efficacy data and safety concerns, including daytime sedation and delirium risk, particularly in vulnerable populations, according to the American Academy of Sleep Medicine 7
Failing to recognize that improvements from CBT-I are gradual but produce durable benefits beyond treatment end, unlike medications which provide only temporary relief, is a common pitfall, as noted by the American Academy of Sleep Medicine 7
Using sleep restriction therapy without caution in patients with seizure disorder or bipolar disorder, as treatment-induced sleep deprivation may worsen these conditions, is a consideration in CBT-I implementation, as per the American Academy of Sleep Medicine 7